{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:24:44Z","timestamp":1791818684029,"version":"4.3.4"},"reference-count":127,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T00:00:00Z","timestamp":1648339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T00:00:00Z","timestamp":1648339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Novel pharmacologic treatment options reduce mortality and morbidity in a cost-effective manner in patients with heart failure (HF). Undisputedly, the effective implementation of these agents is an essential element of good clinical practice, which is endorsed by the European Society of Cardiology (ESC) guidelines on acute and chronic HF. Yet, physicians struggle to implement these therapies as they have to balance the true and\/or perceived risks versus their substantial benefits in clinical practice. Any worsening of biomarkers of renal function is often perceived as being disadvantageous and is in clinical practice one of the most common reasons for ineffective drug implementation. However, even in this context, they clearly reduce mortality and morbidity in HF with reduced ejection fraction (HFrEF) patients, even in patients with poor renal function. Furthermore these agents are also beneficial in HF with mildly reduced ejection fraction (HFmrEF) and sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors more recently demonstrated a beneficial effect in HF with preserved ejection fraction (HFpEF). The emerge of several new classes (angiotensin receptor\u2013neprilysin inhibitor [ARNI], SGLT2 inhibitors, vericiguat, omecamtiv mecarbil) and the recommendation by the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic HF of early initiation and titration of quadruple disease-modifying therapies (ARNI\/angiotensin-converting enzyme inhibitor + beta-blocker + mineralocorticoid receptor antagonist and SGLT2 inhibitor) in HFrEF increases the likelihood of treatment-induced changes in renal function. This may be (incorrectly) perceived as deleterious, resulting in inertia of starting and uptitrating these lifesaving therapies. Therefore, the objective of this consensus document is to provide advice of the effect HF drugs on renal function.<\/jats:p>","DOI":"10.1002\/ejhf.2471","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T09:59:57Z","timestamp":1646301597000},"page":"603-619","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Renal Effects of Guideline-Directed Medical Therapies in Heart Failure: A Consensus Document from the Heart Failure Association of the European Society of Cardiology"],"prefix":"10.1093","volume":"24","author":[{"given":"Wilfried","family":"Mullens","sequence":"first","affiliation":[{"name":"Ziekenhuis Oost Limburg, Genk, University Hasselt , Hasselt ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Martens","sequence":"additional","affiliation":[{"name":"Ziekenhuis Oost Limburg, Genk, University Hasselt , Hasselt ,","place":["Belgium"]},{"name":"Cleveland Clinic , Cleveland, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Testani","sequence":"additional","affiliation":[{"name":"Yale University , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.H. Wilson","family":"Tang","sequence":"additional","affiliation":[{"name":"Cleveland Clinic , Cleveland, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Skouri","sequence":"additional","affiliation":[{"name":"American University of Beirut Medical Center-Beirut , Beirut ,","place":["Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik H.","family":"Verbrugge","sequence":"additional","affiliation":[{"name":"Centre for Cardiovascular Diseases, University Hospital Brussel , Jette ,","place":["Belgium"]},{"name":"Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel , Brussels ,","place":["Belgium"]},{"name":"Faculty of Medicine and Life Sciences, Hasselt University , Hasselt ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Fudim","sequence":"additional","affiliation":[{"name":"Duke University Medical Center , Durham, NC ,","place":["USA"]},{"name":"Duke Clinical Research Institute , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Iacoviello","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Foggia , Foggia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Franke","sequence":"additional","affiliation":[{"name":"CardioVascular Center Frankfurt , Frankfurt ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas J.","family":"Flammer","sequence":"additional","affiliation":[{"name":"University Heart Center, University Hospital Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Palazzuoli","sequence":"additional","affiliation":[{"name":"Cardiovascular Diseases Unit, Department of Medical Sciences, Le Scotte Hospital Siena , Siena ,","place":["Italy"]},{"name":"School of Nursing and Midwifery, Queen's University , Belfast ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Morejon","family":"Barragan","sequence":"additional","affiliation":[{"name":"Clinica Guayaquil , Guayaquil ,","place":["Ecuador"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Thum","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School , Hannover ,","place":["Germany"]},{"name":"Fraunhofer Institute of Toxicology and Experimental Medicine , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Cobo","family":"Marcos","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta de Hierro Majadahonda, CIBERCV , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d2scar","family":"Mir\u00f3","sequence":"additional","affiliation":[{"name":"Emergency Department, Hospital Cl\u00ednic, Barcelona, IDIBAPS, University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm 1433 CIC-P CHRU de Nancy, Inserm U1116, and F-CRIN INI-CRCT , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lassus","sequence":"additional","affiliation":[{"name":"Heart and Lung Center, Cardiology, University of Helsinki and Helsinki University Hospital , Helsinki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Orso","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli studi di Firenze , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa A.","family":"Jankowska","sequence":"additional","affiliation":[{"name":"Institute of Heart Diseases, Wroclaw Medical University and Institute of Heart Diseases, University Hospital in Wroclaw , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu","family":"Chioncel","sequence":"additional","affiliation":[{"name":"Emergency Institute for Cardiovascular Diseases \u2018Prof. C.C. Iliescu\u2019, University of Medicine Carol Davila , Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davor","family":"Milicic","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, University of Zagreb School of Medicine & University Hospital Centre Zagreb , Zagreb ,","place":["Croatia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreena","family":"Hill","sequence":"additional","affiliation":[{"name":"School of Nursing & Midwifery, Queen's University , Belfast ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar","family":"Seferovic","sequence":"additional","affiliation":[{"name":"Universi Faculty of Medicine, University of Belgrade, and Serbian Academy of Arts and Sciences , Belgrade ,","place":["Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rosano","sequence":"additional","affiliation":[{"name":"St George's University Medical School of London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Coats","sequence":"additional","affiliation":[{"name":"University of Warwick , Coventry ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Damman","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,27]]},"reference":[{"key":"2026080801020585800_ejhf2471-bib-0001","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ejhf.1531","article-title":"Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0003","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ejhf.1697","article-title":"Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Mullens","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0004","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ejhf.510","article-title":"Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey","volume":"18","author":"Komajda","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0005","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"2026080801020585800_ejhf2471-bib-0006","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026080801020585800_ejhf2471-bib-0007","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080801020585800_ejhf2471-bib-0008","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026080801020585800_ejhf2471-bib-0009","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080801020585800_ejhf2471-bib-0010","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/ejhf.1793","article-title":"Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP heart failure long-term registry","volume":"22","author":"Rossignol","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0011","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026080801020585800_ejhf2471-bib-0012","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1152\/ajplegacy.1972.223.5.1191","article-title":"Dynamics of glomerular ultrafiltration in the rat. 3. Hemodynamics and autoregulation","volume":"223","author":"Robertson","year":"1972","journal-title":"Am J Physiol"},{"key":"2026080801020585800_ejhf2471-bib-0013","first-page":"F477","article-title":"An analysis of the determinants of nephron filtration rate","volume":"232","author":"Tucker","year":"1977","journal-title":"Am J Physiol"},{"key":"2026080801020585800_ejhf2471-bib-0014","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1152\/ajplegacy.1975.228.1.127","article-title":"Autoregulation of blood flow in the rat kidney","volume":"228","author":"Arendshorst","year":"1975","journal-title":"Am J Physiol"},{"key":"2026080801020585800_ejhf2471-bib-0015","doi-asserted-by":"crossref","first-page":"11993","DOI":"10.1073\/pnas.89.24.11993","article-title":"Nitric oxide synthase in macula densa regulates glomerular capillary pressure","volume":"89","author":"Wilcox","year":"1992","journal-title":"Proc Natl Acad Sci U\u2009S\u2009A"},{"key":"2026080801020585800_ejhf2471-bib-0016","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1152\/ajplegacy.1972.223.5.1184","article-title":"Dynamics of glomerular ultrafiltration in the rat. II. Plasma-flow dependence of GFR","volume":"223","author":"Brenner","year":"1972","journal-title":"Am J Physiol"},{"key":"2026080801020585800_ejhf2471-bib-0017","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1161\/01.RES.36.3.425","article-title":"Dynamics of glomerular ultrafiltration in the rat. VIII. Effects of hematocrit","volume":"36","author":"Myers","year":"1975","journal-title":"Circ Res"},{"key":"2026080801020585800_ejhf2471-bib-0018","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/ki.1982.5","article-title":"Ultrafiltration coefficient and glomerular capillary resistance a model of immune complex glomerulonephritis","volume":"21","author":"Savin","year":"1982","journal-title":"Kidney Int"},{"key":"2026080801020585800_ejhf2471-bib-0019","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/eurheartj\/ehx035","article-title":"Renal sodium avidity in heart failure: from pathophysiology to treatment strategies","volume":"38","author":"Mullens","year":"2017","journal-title":"Eur Heart J"},{"key":"2026080801020585800_ejhf2471-bib-0020","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003825","article-title":"Heart failure increases the risk of adverse renal outcomes in patients with normal kidney function","volume":"10","author":"George","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0021","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ejhf.35","article-title":"The kidney in congestive heart failure: \u2018are natriuresis, sodium, and diuretics really the good, the bad and the ugly?","volume":"16","author":"Verbrugge","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0022","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000109967","article-title":"Effect of long-term type 1 diabetes on renal sodium and water transporters in rats","volume":"28","author":"Vidotti","year":"2008","journal-title":"Am J Nephrol"},{"key":"2026080801020585800_ejhf2471-bib-0023","doi-asserted-by":"crossref","first-page":"27869","DOI":"10.1074\/jbc.M110.133066","article-title":"Activation of Na+\/H+ exchanger NHE3 by angiotensin II is mediated by inositol 1,4,5-triphosphate (IP3) receptor-binding protein released with IP3 (IRBIT) and Ca2+\/calmodulin-dependent protein kinase II","volume":"285","author":"He","year":"2010","journal-title":"J Biol Chem"},{"key":"2026080801020585800_ejhf2471-bib-0024","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00232-010-9334-6","article-title":"Glucose-induced regulation of NHEs activity and SGLTs expression involves the PKA signaling pathway","volume":"239","author":"Beloto-Silva","year":"2011","journal-title":"J Membr Biol"},{"key":"2026080801020585800_ejhf2471-bib-0025","doi-asserted-by":"crossref","first-page":"688","DOI":"10.2337\/db07-1230","article-title":"The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes","volume":"57","author":"Cherney","year":"2008","journal-title":"Diabetes"},{"key":"2026080801020585800_ejhf2471-bib-0026","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"2026080801020585800_ejhf2471-bib-0027","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1161\/01.CIR.102.2.203","article-title":"Renal function, neurohormonal activation, and survival in patients with chronic heart failure","volume":"102","author":"Hillege","year":"2000","journal-title":"Circulation"},{"key":"2026080801020585800_ejhf2471-bib-0028","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080801020585800_ejhf2471-bib-0029","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.cardfail.2007.04.008","article-title":"Worsening renal function and prognosis in heart failure: systematic review and meta-analysis","volume":"13","author":"Damman","year":"2007","journal-title":"J Card Fail"},{"key":"2026080801020585800_ejhf2471-bib-0030","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/j.jacc.2005.11.084","article-title":"Renal impairment and outcomes in heart failure: systematic review and meta-analysis","volume":"47","author":"Smith","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026080801020585800_ejhf2471-bib-0031","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/ejhf.872","article-title":"Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"19","author":"Harjola","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0032","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/j.ajkd.2018.07.015","article-title":"Effects of intensive blood pressure lowering on kidney tubule injury in CKD: a longitudinal subgroup analysis in SPRINT","volume":"73","author":"Malhotra","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2026080801020585800_ejhf2471-bib-0033","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.jacc.2008.03.009","article-title":"The right ventricular failure risk score: a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates","volume":"51","author":"Matthews","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026080801020585800_ejhf2471-bib-0034","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2008.05.068","article-title":"Importance of venous congestion for worsening of renal function in advanced decompensated heart failure","volume":"53","author":"Mullens","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026080801020585800_ejhf2471-bib-0035","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/j.jacc.2016.03.537","article-title":"Cardiac output and renal dysfunction: definitely more than impaired flow","volume":"67","author":"Mullens","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026080801020585800_ejhf2471-bib-0036","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCHEARTFAILURE.111.963413","article-title":"Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function","volume":"5","author":"Metra","year":"2012","journal-title":"Circ Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0037","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ahj.2018.07.019","article-title":"Worsening renal function during decongestion among patients hospitalized for heart failure: findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial","volume":"204","author":"Fudim","year":"2018","journal-title":"Am Heart J"},{"key":"2026080801020585800_ejhf2471-bib-0038","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1080\/08860220701641777","article-title":"Acute effect of furosemide on glomerular filtration rate in diastolic dysfunction","volume":"29","author":"Trivedi","year":"2007","journal-title":"Ren Fail"},{"key":"2026080801020585800_ejhf2471-bib-0039","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1161\/CIRCULATIONAHA.109.933275","article-title":"Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival","volume":"122","author":"Testani","year":"2010","journal-title":"Circulation"},{"key":"2026080801020585800_ejhf2471-bib-0040","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jacc.2013.05.027","article-title":"Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion","volume":"62","author":"Testani","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080801020585800_ejhf2471-bib-0041","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.amjcard.2013.08.013","article-title":"Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions","volume":"112","author":"Verbrugge","year":"2013","journal-title":"Am J Cardiol"},{"key":"2026080801020585800_ejhf2471-bib-0042","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1614329","article-title":"Single-nephron glomerular filtration rate in healthy adults","volume":"376","author":"Denic","year":"2017","journal-title":"N Engl J Med"},{"key":"2026080801020585800_ejhf2471-bib-0043","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ejhf.30","article-title":"Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey","volume":"16","author":"van Deursen","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0044","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ki.2008.200","article-title":"Gender differences in predictors of the decline of renal function in the general population","volume":"74","author":"Halbesma","year":"2008","journal-title":"Kidney Int"},{"key":"2026080801020585800_ejhf2471-bib-0045","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.cardfail.2016.09.006","article-title":"Progression of renal impairment and chronic kidney disease in chronic heart failure: an analysis from GISSI-HF","volume":"23","author":"Damman","year":"2017","journal-title":"J Card Fail"},{"key":"2026080801020585800_ejhf2471-bib-0046","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA"},{"key":"2026080801020585800_ejhf2471-bib-0047","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2026080801020585800_ejhf2471-bib-0048","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2026080801020585800_ejhf2471-bib-0049","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","article-title":"Aliskiren, enalapril, or aliskiren and enalapril in heart failure","volume":"374","author":"McMurray","year":"2016","journal-title":"N Engl J Med"},{"key":"2026080801020585800_ejhf2471-bib-0050","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1161\/CIRCULATIONAHA.111.028282","article-title":"Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study","volume":"125","author":"Rossignol","year":"2012","journal-title":"Circulation"},{"key":"2026080801020585800_ejhf2471-bib-0051","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jchf.2018.02.017","article-title":"Exploiting the natriuretic peptide pathway to preserve glomerular filtration in heart failure","volume":"6","author":"Mullens","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0052","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ejhf.2086","article-title":"Empagliflozin and renal sodium handling: an intriguing smart osmotic diuretic","volume":"23","author":"Mullens","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0053","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008537","article-title":"Pitfalls in using estimated glomerular filtration rate slope as a surrogate for the effect of drugs on the risk of serious adverse renal outcomes in clinical trials of patients with heart failure","volume":"14","author":"Packer","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0054","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026080801020585800_ejhf2471-bib-0055","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","article-title":"Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference","volume":"95","author":"House","year":"2019","journal-title":"Kidney Int"},{"key":"2026080801020585800_ejhf2471-bib-0056","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0002-9343(84)90882-9","article-title":"Glomerular actions of angiotensin II","volume":"76","author":"Ichikawa","year":"1984","journal-title":"Am J Med"},{"key":"2026080801020585800_ejhf2471-bib-0057","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ejhf.958","article-title":"Acute kidney injury in cardiogenic shock: definitions, incidence, haemodynamic alterations, and mortality","volume":"20","author":"Tarvasmaki","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0058","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.ajpath.2011.06.033","article-title":"Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway","volume":"179","author":"Nijenhuis","year":"2011","journal-title":"Am J Pathol"},{"key":"2026080801020585800_ejhf2471-bib-0059","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1001\/archinte.160.17.2645","article-title":"Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function","volume":"160","author":"Frances","year":"2000","journal-title":"Arch Intern Med"},{"key":"2026080801020585800_ejhf2471-bib-0060","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/01.CIR.0000116764.53225.A9","article-title":"Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study","volume":"109","author":"McAlister","year":"2004","journal-title":"Circulation"},{"key":"2026080801020585800_ejhf2471-bib-0061","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"Yusuf","year":"1992","journal-title":"N Engl J Med"},{"key":"2026080801020585800_ejhf2471-bib-0062","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.amjmed.2011.10.013","article-title":"Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease","volume":"125","author":"Ahmed","year":"2012","journal-title":"Am J Med"},{"key":"2026080801020585800_ejhf2471-bib-0063","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jacc.2013.11.031","article-title":"Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data","volume":"63","author":"Damman","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080801020585800_ejhf2471-bib-0064","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.kint.2019.05.019","article-title":"Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction","volume":"96","author":"McCallum","year":"2019","journal-title":"Kidney Int"},{"key":"2026080801020585800_ejhf2471-bib-0065","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/j.ajkd.2019.05.010","article-title":"Trends in kidney function outcomes following RAAS inhibition in patients with heart failure with reduced ejection fraction","volume":"75","author":"McCallum","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026080801020585800_ejhf2471-bib-0066","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2026080801020585800_ejhf2471-bib-0067","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int"},{"key":"2026080801020585800_ejhf2471-bib-0068","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrneph.2010.30","article-title":"Aldosterone: effects on the kidney and cardiovascular system","volume":"6","author":"Briet","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"2026080801020585800_ejhf2471-bib-0069","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026080801020585800_ejhf2471-bib-0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","article-title":"Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0071","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080801020585800_ejhf2471-bib-0072","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1152\/ajplegacy.1969.217.3.764","article-title":"Renal vascular responses to isoproterenol","volume":"217","author":"Mark","year":"1969","journal-title":"Am J Physiol"},{"key":"2026080801020585800_ejhf2471-bib-0073","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1172\/JCI107207","article-title":"Mechanism of effect of alpha adrenergic stimulation with norepinephrine on renal water excretion","volume":"52","author":"Schrier","year":"1973","journal-title":"J Clin Invest"},{"key":"2026080801020585800_ejhf2471-bib-0074","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jacc.2011.04.041","article-title":"Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"58","author":"Badve","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026080801020585800_ejhf2471-bib-0075","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1161\/CIRCHEARTFAILURE.109.932558","article-title":"Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials","volume":"4","author":"Wali","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0076","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.cardfail.2008.11.003","article-title":"The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR\/XL Randomized Intervention Trial in Chronic HF (MERIT-HF)","volume":"15","author":"Ghali","year":"2009","journal-title":"J Card Fail"},{"key":"2026080801020585800_ejhf2471-bib-0077","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1016\/j.jacc.2019.09.059","article-title":"Impact of renal impairment on beta-blocker efficacy in patients with heart failure","volume":"74","author":"Kotecha","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080801020585800_ejhf2471-bib-0078","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/eurjhf\/hfq038","article-title":"Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) trial","volume":"12","author":"Castagno","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0079","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","article-title":"Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial","volume":"41","author":"Cice","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026080801020585800_ejhf2471-bib-0080","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2215\/CJN.07470717","article-title":"Beta-blocker dialyzability in maintenance hemodialysis patients: a randomized clinical trial","volume":"13","author":"Tieu","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026080801020585800_ejhf2471-bib-0081","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0082","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction","volume":"142","author":"Mc Causland","year":"2020","journal-title":"Circulation"},{"key":"2026080801020585800_ejhf2471-bib-0083","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1152\/advan.00177.2016","article-title":"The renal and cardiovascular effects of natriuretic peptides","volume":"41","author":"Wong","year":"2017","journal-title":"Adv Physiol Educ"},{"key":"2026080801020585800_ejhf2471-bib-0084","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1152\/physrev.1990.70.3.665","article-title":"Diverse biological actions of atrial natriuretic peptide","volume":"70","author":"Brenner","year":"1990","journal-title":"Physiol Rev"},{"key":"2026080801020585800_ejhf2471-bib-0085","first-page":"F415","article-title":"Direct vasodilatory action of atrial natriuretic factor on canine glomerular afferent arterioles","volume":"255","author":"Ohishi","year":"1988","journal-title":"Am J Physiol"},{"key":"2026080801020585800_ejhf2471-bib-0086","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1517\/13543784.13.6.643","article-title":"Recent advances in natriuretic peptides in congestive heart failure","volume":"13","author":"Boerrigter","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"key":"2026080801020585800_ejhf2471-bib-0087","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ejhf.232","article-title":"Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction","volume":"17","author":"Voors","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0088","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S2213-8587(18)30100-1","article-title":"Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial","volume":"6","author":"Packer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026080801020585800_ejhf2471-bib-0089","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jchf.2020.08.014","article-title":"Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in PARAGON-HF","volume":"9","author":"Jering","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0090","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"2026080801020585800_ejhf2471-bib-0091","doi-asserted-by":"crossref","first-page":"F156","DOI":"10.1152\/ajprenal.00409.2012","article-title":"Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus","volume":"304","author":"Vallon","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026080801020585800_ejhf2471-bib-0092","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"2026080801020585800_ejhf2471-bib-0093","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"2026080801020585800_ejhf2471-bib-0094","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"key":"2026080801020585800_ejhf2471-bib-0095","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/ki.2014.246","article-title":"Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes","volume":"86","author":"Cherney","year":"2014","journal-title":"Kidney Int"},{"key":"2026080801020585800_ejhf2471-bib-0096","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"2026080801020585800_ejhf2471-bib-0097","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation"},{"key":"2026080801020585800_ejhf2471-bib-0098","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"2026080801020585800_ejhf2471-bib-0099","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.121.054669","article-title":"Kidney function after initiation and discontinuation of empagliflozin in heart failure patients with and without type 2 diabetes: insights from the EMPERIAL trials","author":"Anker","year":"2021","journal-title":"Circulation"},{"key":"2026080801020585800_ejhf2471-bib-0100","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1056\/NEJMc2112411","article-title":"Empagliflozin and major renal outcomes in heart failure","volume":"385","author":"Packer","year":"2021","journal-title":"N Engl J Med"},{"key":"2026080801020585800_ejhf2471-bib-0101","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial","volume":"143","author":"Nassif","year":"2021","journal-title":"Circulation"},{"key":"2026080801020585800_ejhf2471-bib-0102","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1002\/ehf2.12850","article-title":"Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring","volume":"7","author":"Mullens","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0103","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2026080801020585800_ejhf2471-bib-0104","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and Cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"2026080801020585800_ejhf2471-bib-0105","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1016\/j.jacc.2020.10.005","article-title":"Effect of empagliflozin on hemodynamics in patients with heart failure and reduced ejection fraction","volume":"76","author":"Omar","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026080801020585800_ejhf2471-bib-0106","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jchf.2021.05.006","article-title":"Empagliflozin-induced changes in epicardial fat: the centerpiece for myocardial protection?","volume":"9","author":"Mullens","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0107","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007046","article-title":"Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects","volume":"7","author":"Wilcox","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026080801020585800_ejhf2471-bib-0108","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2337\/db12-0052","article-title":"Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?","volume":"61","author":"Liu","year":"2012","journal-title":"Diabetes"},{"key":"2026080801020585800_ejhf2471-bib-0109","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ejhf.2066","article-title":"Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure","volume":"23","author":"Boorsma","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0111","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jchf.2020.11.009","article-title":"Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF","volume":"9","author":"Shen","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0112","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/ejhf.59","article-title":"The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT","volume":"16","author":"Voors","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0113","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1515\/hsz-2018-0155","article-title":"From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators","volume":"399","author":"Sandner","year":"2018","journal-title":"Biol Chem"},{"key":"2026080801020585800_ejhf2471-bib-0114","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2215\/CJN.08410520","article-title":"Effects of the soluble guanylate cyclase stimulator praliciguat in diabetic kidney disease: a randomized placebo-controlled clinical trial","volume":"16","author":"Hanrahan","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026080801020585800_ejhf2471-bib-0115","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080801020585800_ejhf2471-bib-0116","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/ejhf.2221","article-title":"Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial","volume":"23","author":"Voors","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0117","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40261-021-01051-4","article-title":"Effect of omecamtiv mecarbil on the pharmacokinetics of metformin, a probe substrate for MATE1\/MATE2-K, in healthy subjects","volume":"41","author":"Trivedi","year":"2021","journal-title":"Clin Drug Investig"},{"key":"2026080801020585800_ejhf2471-bib-0118","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"key":"2026080801020585800_ejhf2471-bib-0119","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion \u2013 a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0120","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/ejhf.2384","article-title":"Worsening renal function in acute heart failure in the context of diuretic response","volume":"24","author":"Emmens","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0121","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1161\/CIRCULATIONAHA.117.030112","article-title":"Worsening renal function in acute heart failure patients undergoing aggressive diuresis is not associated with tubular injury","volume":"137","author":"Ahmad","year":"2018","journal-title":"Circulation"},{"key":"2026080801020585800_ejhf2471-bib-0122","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1002\/ehf2.13666","article-title":"Rationale and design of the efficacy of a standardized diuretic protocol in acute heart failure study","volume":"8","author":"Dauw","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0123","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ejhf.2385","article-title":"Natriuresis-guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial","volume":"24","author":"Ter Maaten","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080801020585800_ejhf2471-bib-0124","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2021.05.002","article-title":"Kidney function and outcomes in patients hospitalized with heart failure","volume":"78","author":"Patel","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026080801020585800_ejhf2471-bib-0125","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008789","article-title":"Reasons for guideline nonadherence at heart failure discharge","volume":"7","author":"Gilstrap","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026080801020585800_ejhf2471-bib-0126","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1001\/jama.2015.11904","article-title":"Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure","volume":"314","author":"Cooper","year":"2015","journal-title":"JAMA"},{"key":"2026080801020585800_ejhf2471-bib-0127","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/ehjqcco\/qcy019","article-title":"A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure","volume":"4","author":"Nilsson","year":"2018","journal-title":"Eur Heart J Qual Care Clin Outcomes"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.2471","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.2471","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/24\/4\/603\/65734483\/eurjhf_24_4_603.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/24\/4\/603\/65734483\/eurjhf_24_4_603.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T05:02:30Z","timestamp":1786165350000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/24\/4\/603\/8364233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,27]]},"references-count":127,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,3,27]]},"published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.2471","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4]]},"published":{"date-parts":[[2022,3,27]]},"assertion":[{"value":"2022-01-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}